Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
weight loss at target dose (trial data) ~15% (STEP 1) CV risk reduction labelled Yes (SELECT obesity + CVD) Format Prefilled pen India price (May 2026) 5,66016,400/month (Poviztra co-marketed: 3,9998,999/month) DCGI-approved Yes (20252026) Generic competition in India n/a (innovator) Generic semaglutide 9+ Indian manufacturers Active molecule Semaglutide Receptor activity GLP-1 Primary indication T2D &/or obesity (brand-dependent) Max maintenance dose 0.52.4 mg weekly Avg
2 Pediatrics Department, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, Enshi Prefecture, 445000, Hubei Province, Peoples Republic of China *These authors contributed equally to this work Correspondence: Yuhua Lei No
Your dose may go up
Access this article Similar content being viewed by others Data Availability This work uses publicly available data released by the U.S
Am J Physiol 279:R1449R1454 Bertsch T, McKeirnan K (2018) ITCA 650
